Cognito Therapeutics vs PhaseV
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
About
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of world's top pharma companies as partners.
About
PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.